Research
Molecular
Variant screening of PYY 3–36 led to the development of highly selective long-acting analogs against the Y 2 receptor.
This suggests potential for new treatments targeting the Y 2 receptor in diabetes.
StrongSupportsmedium confidence
This afforded highly selective long-acting analogs against the Y 2 receptor.
Why this rating
Based on the systematic approach described in the abstract.
Source
Variant screening of PYY <sub>3–36</sub> leads to potent long-acting PYY analogs with superior Y <sub>2</sub> receptor selectivity
Søren Østergaard et al. · Science Translational Medicine · 2025
DOI 10.1126/scitranslmed.adq6392
otherCited 8×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Molecular
- QRISK decreased markedly after weight loss from 18.9 ± 2.2% to 11.2 ± 1.6%, p < 0.0001.Strong
- Normalization of 10-year cardiovascular risk and heart age is possible after substantial dietary weight loss and remission of T2DM.Strong
- The Low-Fat Plus diet resulted in a greater reduction in total cholesterol compared to the Low-Fat diet, with changes of -0.46 mmol/L (-17.6 mg/dL) versus -0.24 mmol/L (-9.2 mg/dL) respectively (P = 0.01).Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →